The biopharmaceutical company Arvinas Inc. has taken a unique approach to develop investigational therapies for hard-to-treat diseases, including cancers. XVIVO, in collaboration with Wyant Simboli and their client, Arvinas Inc., helped communicate the unconventional mechanism of action for a new class of drugs that engage the body’s own protein disposal system to target cancers and other difficult-to-treat diseases.

Arvinas’ approach is to tag a protein implicated in a disease with their proprietary Proteolysis-Targeting Chimera, or PROTAC. PROTACs are small molecules that can be tailored to tag particular proteins. The PROTAC also binds to a naturally-occurring protein that ultimately results in the disease protein being degraded by the body’s natural disposal system.

XVIVO initially created an illustration for Arvinas to showcase the multiple steps in the body’s pathway for protein degradation and the tunable structure of the PROTAC molecule. Following the success of that project, Arvinas asked XVIVO to expand the concepts in the illustration to a 3D animation.

Learn more about this illustration in our blog, Illustrating the Unconventional: PROTAC™ Technology for Disease Therapy.

Related Illustrations

ARM™ MATE™ Comparison MOA

ARM™ MATE™ Comparison MOA